Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an Expanded Access Program

Clinical Lung Cancer

Volumn 7, Issue 5, 2006, Pages 326-331

  Thomas, Sheeba K ^a   Fossella, Frank V ^a   Liu, Diane ^a   Schaerer, Rainell ^a   Tsao, Anne S ^a   Kies, Merrill S ^a   Pisters, Katherine M ^a   Blumenschein Jr , George R ^a   Glisson, Bonnie S ^a   Lee, J Jack ^a   Herbst, Roy S ^a   Zinner, Ralph G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ASIAN; CANCER GROWTH; CANCER SURVIVAL; CAUCASIAN; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; ETHNOLOGY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INDEPENDENT VARIABLE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PARONYCHIA; PASSIVE SMOKING; PREDICTION; RETROSPECTIVE STUDY; REVIEW; SMOKING; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UNIVARIATE ANALYSIS; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 33745001221     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.014     Document Type: Article

References (13)

1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [published erratum in J Clin Oncol 2004; 22:4811]. J Clin Oncol 2003; 21:2237-2246.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
3. Giaccone G, Herbst RS, Manegold C. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22:777-784.
4. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22:785-794.
5. Shepherd FA, Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
6. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval Summary: gefitinib (ZD 1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-1217.
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
8. Tsao AS, Liu D, Kies M, et al. Smoking impacts response in NSCLC patients treated with Gefitinib (Iressa). Presented at: the Proceedings of the American Association for Cancer Research and the Japanese Cancer Association Meeting; January 24-29, 2004; Waikoloa, HI.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
10. World Health Organization (WHO) Common Toxicity Criteria, Revision 2.0. Available at: http://ctep.cancer.gov/forms/ctcv2nom-4-30-99-final3.pdf. Accessed December 15, 2004.
11. Response Evaluation Criteria in Solid Tumors (RECIST). Available at: http://www3.cancer.gov/bip/RECIST.htm. Accessed December 15, 2004.
12. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360.
13. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597.